MCL Literature Feed
797 papers on mantle cell lymphoma from PubMed. Updated daily.
This case report details a rare MCL-induced paraneoplastic 'full-house' nephropathy mimicking lupus nephritis, which resolved with lymphoma-directed therapy, expanding the spectrum of known renal complications.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This general review of lymphoproliferative disorders reiterates the established role of bortezomib in relapsed/refractory mantle cell lymphoma but provides no new data or specific insights.
This review highlights the improved cardiovascular safety of next-generation BTK inhibitors over ibrutinib, which is critical for MCL treatment selection and long-term management of associated cardiac toxicities.
Mendelian randomization provides genetic evidence that obesity is a causal risk factor for developing mantle cell lymphoma, identifying a potentially modifiable risk factor for the disease.
This preclinical mouse study shows zanubrutinib mitigates pulmonary fibrosis by inhibiting the Wnt/β-catenin pathway, a novel off-target mechanism potentially relevant to managing toxicities in MCL patients.
In the phase 3 TRIANGLE trial for young, fit MCL, adding ibrutinib to induction immunochemotherapy improves failure-free survival, with noninvasive genotyping confirming its efficacy and treatment dynamics.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
A new genomic model integrating mutations (e.g., TP53) and copy number variations improves risk stratification for elderly, newly diagnosed MCL patients treated with chemoimmunotherapy.
This review summarizes the shift towards frontline BTK inhibitor-based regimens, including chemotherapy-free options and combinations for high-risk MCL, potentially replacing autologous stem cell transplant consolidation.
A matching-adjusted indirect comparison suggests pirtobrutinib improves survival versus standard of care for relapsed/refractory MCL patients who have progressed on a prior covalent BTKi, supporting its use.
Emapalumab, an interferon-gamma blocker, successfully treated severe immune effector cell-associated HLH-like syndrome (IEC-HS) in a relapsed MCL patient post-CAR-T, offering a targeted approach for this life-threatening toxicity.
The phase 3 TRIANGLE trial shows adding ibrutinib to frontline chemoimmunotherapy and autologous transplant improves failure-free survival, establishing a new standard of care for young, fit MCL patients.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This review summarizes mechanisms of resistance and relapse after CAR-T/CAR-NK therapy, such as antigen loss and T-cell exhaustion, offering insights for improving durability in MCL.
This multi-center study provides real-world data on treatment outcomes for elderly mantle cell lymphoma patients, offering crucial insights for managing this common and clinically challenging population.
This paper on rhinosinusitis in a general post-transplant population is not specific to mantle cell lymphoma and provides no new insights for the MCL field.
Nintedanib rapidly reversed severe, steroid-resistant post-COVID-19 lung fibrosis in an immunocompromised mantle cell lymphoma patient, highlighting a potential therapy for this specific respiratory complication.
In the MCL0208 trial for young patients, IGHV mutation status and stereotyped receptors predicted outcomes after intensive chemoimmunotherapy and transplant, offering a new biomarker for frontline risk stratification.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This case report demonstrates CD19 downregulation as a key mechanism of resistance and subsequent relapse in a heavily pretreated MCL patient following initially effective CD19-targeted CAR-T therapy.
A rare case of MCL presenting as a parotid gland neoplasm highlights the importance of considering systemic lymphoma in atypical head/neck masses to ensure timely diagnosis and therapy.
This case report identifies ANCA-positive pauci-immune glomerulonephritis as a rare initial presentation of MCL, emphasizing the need to consider underlying malignancy in patients with this renal pathology.
A new prognostic model integrating peripheral blood immune cells and cytokines with clinical data improves risk stratification in MCL, offering a more accessible biomarker approach than tissue-based assays.
This real-world Colombian cohort confirms MIPI score as a key prognostic factor in MCL, where age-stratified frontline chemotherapy resulted in comparable responses despite different treatment intensities.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
Prophylactic siltuximab, guided by rising CRP, effectively managed cytokine release syndrome from bispecifics while minimizing infections by avoiding corticosteroids, a promising toxicity management strategy for MCL patients.
In a large low-grade lymphoma cohort, MCL histology was a key risk factor for lymphoma-related death, while secondary malignancies drove non-lymphoma mortality, underscoring diverse survival threats.
This case report describes an early-onset disseminated adenovirus infection after CAR-T therapy for relapsed/refractory MCL, highlighting a critical and potentially fatal infectious toxicity of this cellular therapy.
Brexucabtagene autoleucel induced a durable 19-month remission in heavily pretreated MCL with intraocular relapse, demonstrating CAR-T efficacy in this rare sanctuary site.
This preclinical study shows a SOX11 inhibitor overcomes BTKi, BCL2i, and CAR-T resistance by targeting the PAX5/CD19 axis, a novel upstream BCR signaling mechanism.